The Effect of Proteinuria on Antinuclear Antibody Assay Results in Patients with Glomerulonephritis

Author(s): Sabahat Sarfaraz*, Sabiha Anis, Ejaz Ahmed, Rana Muzaffar

Journal Name: Applied Clinical Research, Clinical Trials and Regulatory Affairs

Volume 7 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Glomerulonephritis mostly results from dysregulated immune system. Impaired immune mechanisms can be primary or secondary to an autoimmune disorder. Antinuclear antibodies (ANA) are hallmark of autoimmunity and are frequently present at high titer (≥ 1: 160). ANA are characterized via anti-double stranded deoxyribonucleic acid (dsDNA) and antiextractable nuclear antigen (ENA) antibodies for the identification of underlying autoimmune disease. Heavy proteinuria can affect assessment of autoantibodies hence special attention is required for the definitive diagnosis in such cases.

Objective: Our aim was to determine impact of heavy proteinuria on ANA titer, anti-dsDNA and anti-ENA antibodies in glomerulonephritis patients.

Methods: 150 glomerulonephritis patients were enrolled in this study. All had antinuclear antibodies, samples were tested for anti-dsDNA and anti-ENA. ANA titer of ≥1:160 was taken significant. Proteinuria was assessed by spot protein/creatinine ratio. Data was analyzed using SPSS software version. 20.

Results: Heavy proteinuria was present in 119(79%) patients. Low ANA titer(≤1:80) was present in 37(25%) patients. Of 33 patients with heavy proteinuria and low ANA titer, ANA was characterized in 11 patients. These include anti-dsDNA(two), anti-SSA(four), anti-Sm (one), antihistones( one), anti-RNP(two), anti-Pm-Scl(one) and anti-ribosomal P protein (two).There was no significant difference in the prevalence of various autoantibodies in patients with high or low ANA titer with heavy proteinuria.

Conclusion: This study highlights the importance of low ANA titer in glomerulonephritis patients in the setting of heavy proteinuria. Significant protein loss may alter actual titer of autoantibodies. Hence in this scenario clinically correlation along with ANA characterization via specific autoantibodies is required for adequate patient management.

Keywords: Antinuclear antibodies, anti-double stranded deoxyribonucleic acid, anti-extractable nuclear antigens, glomerulonephritis, systemic lupus erythematosus, dysregulated immune system.

[1]
Vinen CS, Oliveira DB. Acute glomerulonephritis. Postgrad Med J 2003; 79(930): 206-13.
[http://dx.doi.org/10.1136/pmj.79.930.206] [PMID: 12743337]
[2]
Kronbichler A, Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC Med 2013; 11: 95.
[http://dx.doi.org/10.1186/1741-7015-11-95] [PMID: 23557013]
[3]
Kurts C, Panzer U, Anders HJ, Rees AJ. The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol 2013; 13(10): 738-53.
[http://dx.doi.org/10.1038/nri3523] [PMID: 24037418]
[4]
Couser WG. Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol 2012; 23(3): 381-99.
[http://dx.doi.org/10.1681/ASN.2011030304] [PMID: 22282593]
[5]
Phan TG, Wong RC, Adelstein S. Autoantibodies to extractable nuclear antigens: making detection and interpretation more meaningful. Clin Diagn Lab Immunol 2002; 9(1): 1-7.
[PMID: 11777822]
[6]
Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 2011; 63(1): 191-200.
[http://dx.doi.org/10.1002/art.30084] [PMID: 20954189]
[7]
Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. Arch Pathol Lab Med 2000; 124(1): 71-81.
[PMID: 10629135]
[8]
Cross LS, Aslam A, Misbah SA. Antinuclear antibody-negative lupus as a distinct diagnostic entity--does it no longer exist? QJM 2004; 97(5): 303-8.
[http://dx.doi.org/10.1093/qjmed/hch048] [PMID: 15100425]
[9]
Kang I, Siperstein R, Quan T, Breitenstein ML. Utility of age, gender, ANA titer and pattern as predictors of anti-ENA and -dsDNA antibodies. Clin Rheumatol 2004; 23(6): 509-15.
[http://dx.doi.org/10.1007/s10067-004-0937-0] [PMID: 15801070]
[10]
Kim HA, Chung JW, Park HJ, et al. An antinuclear antibody-negative patient with lupus nephritis. Korean J Intern Med (Korean Assoc Intern Med) 2009; 24(1): 76-9.
[http://dx.doi.org/10.3904/kjim.2009.24.1.76] [PMID: 19270487]
[11]
Kumar Y, Bhatia A, Minz RW. Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited. Diagn Pathol 2009; 4: 1.
[http://dx.doi.org/10.1186/1746-1596-4-1] [PMID: 19121207]
[12]
Satoh M, Vázquez-Del M M, Chan EK. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 2009; 19(3): 219-28.
[http://dx.doi.org/10.3109/s10165-009-0155-3] [PMID: 19277826]
[13]
Agarwal SK, Sethi S, Dinda AK. Basics of kidney biopsy: A nephrologist’s perspective. Indian J Nephrol 2013; 23(4): 243-52.
[http://dx.doi.org/10.4103/0971-4065.114462] [PMID: 23960337]
[14]
Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest 2001; 108(10): 1417-22.
[http://dx.doi.org/10.1172/JCI14452] [PMID: 11714731]
[15]
Vasoo S. Drug-induced lupus: an update. Lupus 2006; 15(11): 757-61.
[http://dx.doi.org/10.1177/0961203306070000] [PMID: 17153847]
[16]
Sui M, Lin Q, Xu Z, et al. Simultaneous positivity for anti-DNA, anti-nucleosome and anti-histone antibodies is a marker for more severe lupus nephritis. J Clin Immunol 2013; 33(2): 378-87.
[http://dx.doi.org/10.1007/s10875-012-9825-6] [PMID: 23100145]
[17]
Cozzani E, Drosera M, Gasparini G, Parodi A. Serology of Lupus Erythematosus: Correlation between Immunopathological features and clinical aspects. Autoimmune Dis 2014; 2014321359
[http://dx.doi.org/10.1155/2014/321359] [PMID: 24649358]
[18]
Wielosz E, Majdan M, Suszek D, Smarz-Widelska I, Korolczuk A, Korobowicz E. Nephrotic syndrome as a clinical manifestation of systemic sclerosis. Rheumatol Int 2007; 27(11): 1087-9.
[http://dx.doi.org/10.1007/s00296-007-0340-7] [PMID: 17429639]
[19]
Sam R, Joshi A, James S, et al. Lupus-like membranous nephropathy: Is it lupus or not? Clin Exp Nephrol 2015; 19(3): 395-402.
[http://dx.doi.org/10.1007/s10157-014-1002-1] [PMID: 24993947]
[20]
Muro Y, Hosono Y, Sugiura K, Ogawa Y, Mimori T, Akiyama M. Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma. Arthritis Res Ther 2015; 17: 57.
[http://dx.doi.org/10.1186/s13075-015-0573-x] [PMID: 25885224]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 7
ISSUE: 2
Year: 2020
Page: [135 - 140]
Pages: 6
DOI: 10.2174/2213476X06666190715140535

Article Metrics

PDF: 10
HTML: 1